Rituximab and escalated chemotherapy in elderly patients with aggressive diffuse large-cell lymphoma: A controlled clinical trial

Cancer Biotherapy and Radiopharmaceuticals

Volumn 22, Issue 2, 2007, Pages 194-199

  Avilés, Agustin ^a,b   Nambo, María Jesus ^a   Castañeda, Claudia ^a   Cleto, Sergio ^a   Neri, Natividad ^a   Murillo, Edgar ^a   Huerta Guzmán, Judith ^a   Contreras, Margarita ^a  

^a HOSPITAL DE ONCOLOGÍA   (Mexico)

^b Plaza Luis Cabrera 5 502 ^*  (Mexico)

Author keywords

Chemotherapy; Malignant lymphoma; Prognostic factors; Rituximab

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; EPIRUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ANAPHYLAXIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RISK; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; ELDERLY CARE; FEMALE; GRANULOCYTOPENIA; HUMAN; INFECTION; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL; EPIRUBICIN; HUMANS; IMMUNOTHERAPY; LYMPHOMA, LARGE-CELL, DIFFUSE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 34250899134     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2006.360     Document Type: Article

References (25)

1. Lichtman SM. Aggressive lymphoma in the elderly. Crit Rev Oncol Hematol 2000;33:119.
2. Sweetenham JW, Williams CJ. Malignant lymphoma in the elderly. Baillieres Clin Haematol 1987;1:493.
3. Dixon DV, Reilan B, Jones SE, et al. Effect of age on therapeutic outcome in advanced diffuse histiocyte lymphoma. J Clin Oncol 1986;4:295.
4. Vose JM, Armitage JO, Weisenburguer DD, et al. The importance of age on survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1988;6:1838.
5. Epelbamum R, Haim N, Leviov M, et al. Full-dose CHOP chemotherapy in elderly patients with non-Hodgkin's lymphoma. Acta Oncol 1995,34:87.
6. Bastion, Y, Blay JY, Divine M, et al. Elderly patients with aggressive non-Hodgkin's lymphoma: Disease presentation, response to treatment, and outcome. J Clin Oncol 1997;15:2945.
7. Gomez H, Hidalgo M, Casnova L, et al. Risk factors associated for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol 1998;16:2065.
8. Martelli M, Guglielmi C, Coluzzi S, et al. P-VABEC: A prospective study of new weekly chemotherapy regimen for elderly aggressive non-Hodgkin's lymphoma. J Clin Oncol 1993;11:2363.
9. Kourouki T, Browman CP, Esmail R, et al. Chemotherapy for older patients with newly diagnosed advanced stage, aggressive histology non-Hodgkin's lymphoma: A systematic review. Ann Intern Med 2002; 136:144.
10. Balducci L, Repetto L. Increased risk of myelotoxicity in elderly patients with non-Hodgkin's lymphoma. Cancer 2004;100:6.
11. Lee KW, Kim DY, Yun T, et al. Doxorubicin-based chemotherapy for diffuse large-cell lymphoma in elderly patients. Cancer 2003;98:2651.
12. Zinzani PL, Storti S, Zaccaria A, et al. Elderly aggressive-histology non-Hodgkin's lymphoma: First-line VNCOP-B regimen, experience in 350 patients. Blood 1999;94:33.
13. Bailey O, Benjamin O, Vrickster D, et al. Non-Hodgkin's lymphoma in patients 80 years of age of older. Ann Oncol 2006;17:928.
14. Feugier P, VanHoof A, Sebran C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large-cell lymphoma. J. Clin Oncol 2005;23:4117.
15. Jansen-Heisner MLG, van Spronder JJ, Lemmers VEPP, et al. A population-based study of severity of comorbidity among patients with non-Hodgkin's lymphoma. Br J Haematol 2005;129:597.
16. Aviles A, Calva, A, Díaz-Maqueo JC, et al. Dose escalation of epirubicin in the CEOP-Bleo regimen: A controlled, clinical trial comparing standard dose for the treatment of diffuse large-cell lymphoma. Leuk Lymphoma 1997;25:319.
17. Avilés A, Nambo MJ, Talavera A, et al. Epirubicin (CEOP-Bleo) versus idauribicin (CIOP-Bleo) in the treatment of elderly patients with aggressive non-Hodgkin's lymphoma. Anticancer Drugs 1997;8:917.
18. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. J. Clin Oncol 1999;17: 1244.
19. Doodduijon JK, van Holt B, van Imhoff GR, et al. CHOP compared with CHOP plus granulocyte colony stimulating factors in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol 2003;21:3041.
20. Pfreundschuh M, Trumper L, Kloess M, et al. CHOP-chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas. Blood 2004;104:634.
21. Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large-cell lymphoma in British Columbia. J Clin Oncol 2005;23:5027.
22. Pfreundschuh M, Trumper L, Ostenborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-lile chemotherapy in young patients with good prognosis diffuse large-cell lymphoma. Lancet Oncol 2006; 7:379.
23. Buske CM, Weingert U, Dreyling V, et al. Current status and perspective of antibody therapy in follicular lymphoma. Haematologica 2006;91:104.
24. Cohen Y, Solal-celigny P, Polliack A. Rituximab therapy for follicular lymphoma. Haematologica 2003;88: 811.
25. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone with maintenance rituximab in older patients with diffuse large-cell lymphoma. J Clin Oncol 2006;24:3121.